Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.

doi:10.1021/jm5002937

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.

Journal of medicinal chemistry - 12 Jun 2014

Panda Manoranjan, Ramachandran Sreekanth, Ramachandran Vasanthi, Shirude Pravin S, Humnabadkar Vaishali, Nagalapur Kavitha, Sharma Sreevalli, Kaur Parvinder, Guptha Supreeth, Narayan Ashwini, Mahadevaswamy Jyothi, Ambady Anisha, Hegde Naina, Rudrapatna Suresh S, Hosagrahara Vinayak P, Sambandamurthy Vasan K, Raichurkar Anandkumar

Abstract excerpt

A novel pyrazolopyridone class of inhibitors was identified from whole cell screening against Mycobacterium tuberculosis (Mtb). The series exhibits excellent bactericidality in vitro, resulting in a 4 log reduction in colony forming units following compound exposure. The significant modulation of minimum inhibitory concentration (MIC) against a Mtb strain overexpressing the Rv3790 gene suggested the target of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Oxidoreductases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antitubercular Agents

Share to Catalytic Domain

Share to Molecular Docking Simulation

Share to Mycobacterium tuberculosis

Share to Oxidoreductases

Share to Pyrazoles

Share to Pyridones

Source

Open in PubMed

Identifiers

PMID: 24818517
DOI: 10.1021/jm5002937

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.PMID 24818517Read ↗

2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.Semantic proximity Read ↗

4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.Semantic proximity Read ↗

Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.Semantic proximity Read ↗

1,4-Azaindole, a Potential Drug Candidate for Treatment of TuberculosisSemantic proximity Read ↗

Biological Profiling Enables Rapid Mechanistic Classification of Phenotypic Screening Hits and Identification of KatG Activation-Dependent Pyridine Carboxamide Prodrugs With Activity Against Mycobacterium tuberculosis.Semantic proximity Read ↗

Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action Studies.Semantic proximity Read ↗

Redirecting raltitrexed from cancer cell thymidylate synthase to Mycobacterium tuberculosis phosphopantetheinyl transferaseSemantic proximity Read ↗

Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessusSemantic proximity Read ↗

Structure and mapping of spontaneous mutational sites of PyrR from Mycobacterium tuberculosis.Semantic proximity Read ↗

Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessusSemantic proximity Read ↗

N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis.Semantic proximity Read ↗

Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular ThiophenesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.